Jeffrey Eisele Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

APLS Quotes by TradingView

Jeffrey Eisele is Chief Development Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 55,312 shares of APLS, which is worth approximately $1.34 Million. The most recent transaction as insider was on Dec 22, 2021, when has been sold 89 shares (Common Stock) at a price of $47.82 per share, resulting in proceeds of $4,256. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 55.3K
3.21% 3M change
3.31% 12M change
Total Value Held $1.34 Million

Jeffrey Eisele Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 22 2021
SELL
Payment of exercise price or tax liability
$4,256 $47.82 p/Share
89 Reduced 1.19%
7,372 Common Stock
Mar 01 2021
BUY
Grant, award, or other acquisition
-
1,250 Added 14.35%
7,461 Common Stock
Jan 28 2021
BUY
Grant, award, or other acquisition
-
5,000 Added 44.6%
6,211 Common Stock
Dec 23 2020
BUY
Grant, award, or other acquisition
-
1,211 Added 50.0%
1,211 Common Stock
JE

Jeffrey Eisele

Chief Development Officer
Waltham, MA

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on APLS